FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 77 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China MOST POPULAR After Saving Thousands of Dogs, Tragedy Strikes Famed Rescue Family January 4, 2022 Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function November 26, 2018 COVID-19 in people with cancer – what we know so far December 4, 2020 Hamlet Drug, Modeled After Protein In Breast Milk, Kills Tumor Cells... June 26, 2019 Load more HOT NEWS Disparities in Cancer Care Between Citizens and Refugees in Lebanon Three-Drug Regimen Improves Protection against GVHD after Stem Cell Transplant World No Tobacco Day 2024: European Societies call for an EU... Will politics keep us from accessing EU science funding?
